Literature DB >> 12453286

Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy.

Takahiro Yamaura1, Akihiro Matsumoto, Akinori Rokuhara, Tetuya Ichijo, Ehji Tanaka, Kazuhiro Hanazaki, Shoji Kajikawa, Kendo Kiyosawa.   

Abstract

We report a case of hepatocellular carcinoma (HCC) that developed 77 months following sustained and complete response to interferon (IFN) therapy for chronic hepatitis C. A 67-year-old Japanese woman presented with a small mass in the liver that was diagnosed as HCC, 77 months after having completed IFN therapy and having shown a complete response to the therapy with sustained normalization of serum aminotransferases and eradication of serum hepatitis C virus (HCV). Hepatitis C virus RNA was also not detected in the resected tumorous and non-tumorous liver tissues by polymerase chain reaction. This suggests that all patients with chronic HCV infection should be followed closely for as long as possible for the potential development of HCC, even after a complete and sustained response to IFN treatment. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453286     DOI: 10.1046/j.1440-1746.2002.02710.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy.

Authors:  Yukiko Ito; Natsuyo Yamamoto; Ryo Nakata; Yoshihisa Kato; Masashi Iori; Keisuke Sakai; Tamiko Takemura; Ryosuke Tateishi; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 2.  Review.

Authors:  Eric R Kallwitz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

3.  Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C.

Authors:  Shinji Takashimizu; Sei-Ichiro Kojima; Junko Nagata; Yasuhiro Nishizaki; Tatehiro Kagawa; Koichi Shiraishi; Tetsuya Mine; Jun-Ichi Kaneko; Norihiro Kokudo; Norihito Watanabe
Journal:  Clin J Gastroenterol       Date:  2011-03-24

4.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

5.  Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.

Authors:  Roland El Braks; Nathalie Ganne-Carrie; Helene Fontaine; Jacques Paries; Veronique Grando-Lemaire; Michel Beaugrand; Stanislas Pol; Jean-Claude Trinchet
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

6.  Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon.

Authors:  Naoki Hotta; Minoru Ayada; Akihiko Okumura; Tetsuya Ishikawa; Ken Sato; Tomohiko Oohashi; Yasutaka Hijikata; Shinichi Kakumu
Journal:  Case Rep Gastroenterol       Date:  2009-07-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.